The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer: Addressing the Unresolved Issues
Open accessAbstract
landscape of early breast cancer has changed dramat- ically with significant advancements in early screening and diagnosis and curative-intent therapies.Indeed, breast cancer-specific survival has improved by 20% during the past 30 years, and 5-year survival is now 98% for early-stage disease. 1 As a consequence, the risk and nature of adjuvant therapy-induced immediate and late-occurring cardiovascular injury have similarly evolved.In women with early breast cancer, particularly those Ͼ65 years of age, cardiovascular disease (CVD) is now the predominant cause of mortality as indicated by Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data. 2 Additionally, these women are also at increased risk of CVD compared with age-matched women without a history of breast cancer. 3ignificant cardiac safety concerns about anticancer therapy were first described by Von Hoff and colleagues, 4 identifying dose-dependent and progressive left ventricular (LV) dysfunction manifesting as symptomatic heart failure in patients receiving anthracyclines.From this work and others, 5,6 anthracycline-induced cardiac toxicity 7,8 is now a well-recognized adverse side effect.More recently, randomized trials have demonstrated that human epidermal growth factor receptor 2 (HER2)-directed monoclonal antibodies (ie, trastuzumab) and newer multitargeted small-molecule inhibitors interfere with molecular pathways crucial to normal cardiac homeostasis, 9 resulting in relatively high incidences of subclinical and overt cardiac toxicity. 10Although cardiac toxicity with newer therapies has demonstrated reversibility, 11 recovery of LV function after treatment cessation is uncertain at this time. 12Thus, to identify those individuals at high risk of cardiac toxicity, baseline measurement of LV ejection fraction (LVEF) is recommended by the American College of Cardiology (ACC) and American Heart Association (AHA) as standard of care for all breast cancer patients being considered for potentially cardiac-toxic treatment regimens. 13,14In addition, measurement of LVEF is Food and Drug Administration (FDA) mandated in all registrational breast cancer adjuvant trials involving an anthracycline-or a trastuzumab-containing regimen.Finally, use of endocrine therapy (eg, tamoxifen and aromatase inhibitors) in women with hormone receptor-positive breast cancer may also increase the risk of cardiovascular complications. 15espite the rapidly changing landscape of breast cancer management and the resultant changes in cardiovascular safety, several critical issues in the emerging field of "cardiooncology" remain unresolved.To ensure that this field keeps pace, a full understanding of the incidence, magnitude, and consequences of cardiovascular side effects of adjuvant therapy is an essential first step in optimizing early breast cancer management.Against this background, the purpose of this article is to comprehensively review several pivotal unaddressed issues concerning the definition, incidence, detection, and clinical importance of cardiac toxicity in early breast cancer.The evidence supporting the efficacy of preventive and treatment strategies is also discussed.In this article, we use the term cardiac toxicity to refer to myocardial injury related to anticancer pharmacological therapies.The principal manifestations of myocardial injury, LV dysfunction and heart failure, are the primary focus of our review.Additional cardiovascular toxicities associated with anticancer therapies, including sequelae of vascular injury (ie, myocardial ischemia/infarction and stroke), are also considered in discussions of CVD events.Finally, the range of potential cardiovascular effects of currently approved adjuvant breast cancer systemic therapies is summarized and highlighted by class of agent in Table 1. Definition and Clinical ImportanceSeveral oncology and cardiology organizations provide definitions for cardiac toxicity that encompass overt clinical events and subclinical injury (Table 2), although there is no universally accepted definition or clinical cut points.In registrational oncology trials, the most widely adopted criteria for adjudicating cardiovascular events is the Common Terminology Criteria for Adverse Events, developed by the National Cancer Institute. 17,18The Common Terminology
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,846
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Self-citationRisk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,414
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary
Klocke, F. J., Baird, M. G., Lorell, B. H., Bateman, T. M., Messer, J. V., Berman, D. S., O’Gara, P. T., Carabello, B. A., Russell, R. O., Cerqueira, M. D., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.08.011 · Cited by 1,303
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji250 · Cited by 1,118
Anthracycline-Induced Cardiomyopathy
Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.095 · Cited by 1,105
Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.635144 · Cited by 1,026
Coombes, R., Kilburn, L., Snowdon, C., Paridaens, R., Coleman, R., Jones, S., Jassem, J., Van de Velde, C., Delozier, T., Alvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 907
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
Patnaik, J. L., Byers, T., DiGuiseppi, C., Dabelea, D., & Denberg, T. D. (2011) · Breast Cancer Research · doi:10.1186/bcr2901 · Cited by 872
Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond
Mann, D. L., & Bristow, M. R. (2005) · Circulation · doi:10.1161/circulationaha.104.500546 · Cited by 867
Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer
Hooning, M. J., Botma, A., Aleman, B. M. P., Baaijens, M. H. A., Bartelink, H., Klijn, J. G. M., Taylor, C. W., & van Leeuwen, F. E. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk064 · Cited by 861
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E., Ewer, M., Keefe, D., Shannon, R. P., Swain, S. M., Brown, A., Fehrenbacher, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4091 · Cited by 808
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Force, T., Krause, D. S., & Van Etten, R. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2106 · Cited by 801
Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., Hagerty, K. L., Somerfield, M. R., & Vaughn, D. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.9777 · Cited by 793
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients
Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Cohen, V., Gosavi, S., Carver, J. R., Wiegers, S. E., Martin, R. P., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.01.006 · Cited by 682
Self-citationPrediction of long-term prognosis in 12 169 men referred for cardiac rehabilitation
Kavanagh, T., Mertens, D. J., Hamm, L. F., Beyene, J., Kennedy, J., Corey, P., & Shephard, R. J. (2002) · Circulation · doi:10.1161/01.cir.0000024413.15949.ed · Cited by 648
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
Ewer, M. S., & Lippman, S. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.827 · Cited by 646
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Cardinale, D., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., Lamantia, G., Colombo, N., Cortinovis, S., Dessanai, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3615 · Cited by 641
Irwin, M. L., Crumley, D., McTiernan, A., Bernstein, L., Baumgartner, R., Gilliland, F. D., Kriska, A., & Ballard‐Barbash, R. (2003) · Cancer · doi:10.1002/cncr.11227 · Cited by 611
Trastuzumab containing regimens for early breast cancer
Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., & D'Amico, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006243.pub2 · Cited by 604
Anthracycline cardiomyopathy monitored by morphologic changes.
Billingham, M. E., Mason, J. W., Bristow, M. R., & Daniels, J. R. (1978) · PubMed · Cited by 586
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
Suter, T. M., Procter, M., van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1611 · Cited by 566
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub4 · Cited by 553
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Tricca LabTech, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., & Fiorentini, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00748-8 · Cited by 551
Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., Cohen, G. I., Emami, B., Gradishar, W. J., Mitchell, R. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2627 · Cited by 540
Perez, E. A., Suman, V. J., Davidson, N. E., Sledge, G. W., Kaufman, P. A., Hudis, C. A., Martino, S., Gralow, J. R., Dakhil, S. R., Ingle, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5467 · Cited by 538
Wojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeböller, H., Toliat, M. R., Suk, E.-K., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.576850 · Cited by 489
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
Özcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hübner, N., Chien, K. R., Birchmeier, C., & Garratt, A. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122249299 · Cited by 473
Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
(2008) · Principles and Practice of Clinical Trial Medicine · doi:10.1016/b978-0-12-373695-6.00022-3 · Cited by 457
Early Breast Cancer Therapy and Cardiovascular Injury
Jones, L. W., Haykowsky, M. J., Swartz, J. J., Douglas, P. S., & Mackey, J. R. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.037 · Cited by 447
Self-citationCardiopulmonary Function and Age-Related Decline Across the Breast Cancer Survivorship Continuum
Jones, L. W., Courneya, K. S., Mackey, J. R., Muss, H. B., Pituskin, E. N., Scott, J. M., Hornsby, W. E., Coan, A. D., Herndon, J. E., Douglas, P. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9014 · Cited by 442
Self-citationWeidemann, F., Jamal, F., Sutherland, G. R., Claus, P., Kowalski, M., Hatle, L., De Scheerder, I., Bijnens, B., & Rademakers, F. E. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00025.2002 · Cited by 407
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., & Ewer, M. S. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60896-3 · Cited by 388
Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility
Telli, M. L., Hunt, S. A., Carlson, R. W., & Guardino, A. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0106 · Cited by 385
Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation
Kavanagh, T., Mertens, D. J., Hamm, L. F., Beyene, J., Kennedy, J., Corey, P., & Shephard, R. J. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.028 · Cited by 380
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Chen, M. H., Kerkelä, R., & Force, T. (2008) · Circulation · doi:10.1161/circulationaha.108.776831 · Cited by 379
Jong, P., Yusuf, S., Rousseau, M. F., Ahn, S. A., & Bangdiwala, S. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13501-5 · Cited by 378
Mukhopadhyay, P., Rajesh, M., Bátkai, S., Kashiwaya, Y., Haskó, G., Liaudet, L., Szabó, C., & Pacher, P. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00795.2008 · Cited by 376
Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women
Love, R. R., Wiebe, D. A., Newcomb, P. A., Cameron, L., Leventhal, H., Jordan, V. C., Feyzi, J., & DeMets, D. L. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-11-860 · Cited by 374
Force, T., & Kolaja, K. L. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3252 · Cited by 363
Irwin, M. L., McTiernan, A., Baumgartner, R. N., Baumgartner, K. B., Bernstein, L., Gilliland, F. D., & Ballard-Barbash, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.036 · Cited by 360
Speyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191203 · Cited by 356
Fisher, P. W., Salloum, F., Das, A., Hyder, H., & Kukreja, R. C. (2005) · Circulation · doi:10.1161/01.cir.0000160359.49478.c2 · Cited by 355
Jones, L. W., Courneya, K. S., Fairey, A. S., & Mackey, J. R. (2004) · Annals of Behavioral Medicine · doi:10.1207/s15324796abm2802_5 · Cited by 353
Self-citationMeta-analysis of vascular and neoplastic events associated with tamoxifen
Braithwaite, R. S., Chlebowski, R. T., Lau, J., George, S., Hess, R., & Col, N. F. (2003) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2003.20724.x · Cited by 338
Jensen, B. V., Skovsgaard, T., & Nielsen, S. L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf132 · Cited by 336
Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study
Doyle, J. J., Neugut, A. I., Jacobson, J. S., Grann, V. R., & Hershman, D. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5841 · Cited by 335
Armstrong, G. T., Plana, J. C., Zhang, N., Srivastava, D., Green, D. M., Ness, K. K., Daniel Donovan, F., Metzger, M. L., Arevalo, A., Durand, J.-B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3584 · Cited by 321
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., & Cipolla, C. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf170 · Cited by 313
Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction
Jones, L. W., Eves, N. D., Haykowsky, M., Freedland, S. J., & Mackey, J. R. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70031-2 · Cited by 309
Self-citationAnthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes
Lim, C. C., Zuppinger, C., Guo, X., Kuster, G. M., Helmes, M., Eppenberger, H. M., Suter, T. M., Liao, R., & Sawyer, D. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308033200 · Cited by 304
Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity
Aries, A., Paradis, P., Lefebvre, C., Schwartz, R. J., & Nemer, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401833101 · Cited by 296
Spallarossa, P., Garibaldi, S., Altieri, P., Fabbi, P., Manca, V., Nasti, S., Rossettin, P., Ghigliotti, G., Ballestrero, A., & Patrone, F. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.05.024 · Cited by 294
Pacher, P., Liaudet, L., Bai, P., Mabley, J. G., Kaminski, P. M., Virág, L., Deb, A., Szabó, E., Ungvári, Z., Wolin, M. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000048192.52098.dd · Cited by 279
McDonald, C. C., Alexander, F. E., Whyte, B. W., Forrest, A. P., & Stewart, H. J. (1995) · BMJ · doi:10.1136/bmj.311.7011.977 · Cited by 276
Liu, X., Gu, X., Li, Z., Li, X., Li, H., Chang, J., Chen, P., Jin, J., Xi, B., Chen, D., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.057 · Cited by 274
De Angelis, A., Piegari, E., Cappetta, D., Marino, L., Filippelli, A., Berrino, L., Ferreira-Martins, J., Zheng, H., Hosoda, T., Rota, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.895771 · Cited by 268
Cardiovascular toxicity caused by cancer treatment: strategies for early detection
Altena, R., Perik, P. J., van Veldhuisen, D. J., de Vries, E. G., & Gietema, J. A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70042-7 · Cited by 257
Efficiency of Atorvastatin in the Protection of Anthracycline-Induced Cardiomyopathy
Acar, Z., Kale, A., Turgut, M., Demircan, S., Durna, K., Demir, S., Meriç, M., & Ağaç, M. T. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.025 · Cited by 255
Sandri, M. T., Salvatici, M., Cardinale, D., Zorzino, L., Passerini, R., Lentati, P., Leon, M., Civelli, M., Martinelli, G., & Cipolla, C. M. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.050153 · Cited by 250
Ewer, M. S., Ali, M. K., Mackay, B., Wallace, S., Valdivieso, M., Legha, S. S., Benjamin, R. S., & Haynie, T. P. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.2.112 · Cited by 244
Hare, J. L., Brown, J. K., Leano, R., Jenkins, C., Woodward, N., & Marwick, T. H. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.05.031 · Cited by 230
Weinstein, D. M., Mihm, M. J., & Bauer, J. A. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39082-2 · Cited by 229
Georgakopoulos, P., Roussou, P., Matsakas, E., Karavidas, A., Anagnostopoulos, N., Marinakis, T., Galanopoulos, A., Georgiakodis, F., Zimeras, S., Kyriakidis, M., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21840 · Cited by 222
Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground?
Ewer, M. S., & Lenihan, D. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8742 · Cited by 207
Pretreatment with Statin Attenuates the Cardiotoxicity of Doxorubicin in Mice
Riad, A., Bien, S., Westermann, D., Becher, P. M., Loya, K., Landmesser, U., Kroemer, H. K., Schultheiss, H. P., & Tschöpe, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3076 · Cited by 205
Huang, C., Zhang, X., Ramil, J. M., Rikka, S., Kim, L., Lee, Y., Gude, N. A., Thistlethwaite, P. A., Sussman, M. A., Gottlieb, R. A., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.902221 · Cited by 203
De Keulenaer, G. W., Doggen, K., & Lemmens, K. (2010) · Circulation Research · doi:10.1161/circresaha.109.205906 · Cited by 201
Walker, J., Bhullar, N., Fallah-Rad, N., Lytwyn, M., Golian, M., Fang, T., Summers, A. R., Singal, P. K., Barac, I., Kirkpatrick, I. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7294 · Cited by 198
Ganame, J., Claus, P., Uyttebroeck, A., Renard, M., D’hooge, J., Bijnens, B., Sutherland, G. R., Eyskens, B., & Mertens, L. (2007) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2007.04.007 · Cited by 194
Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
Cheng, H., & Force, T. (2010) · Circulation Research · doi:10.1161/circresaha.109.206920 · Cited by 192
Kim, Y., Ma, A.-G., Kitta, K., Fitch, S. N., Ikeda, T., Ihara, Y., Simon, A. R., Evans, T., & Suzuki, Y. J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.368 · Cited by 188
Scott, J. M., Khakoo, A., Mackey, J. R., Haykowsky, M. J., Douglas, P. S., & Jones, L. W. (2011) · Circulation · doi:10.1161/circulationaha.111.021774 · Cited by 188
Self-citationJurcut, R., Wildiers, H., Ganame, J., D'hooge, J., De Backer, J., Denys, H., Paridaens, R., Rademakers, F., & Voigt, J.-U. (2008) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2008.10.005 · Cited by 187
Gordon, L. I., Burke, M. A., Singh, A. T. K., Prachand, S., Lieberman, E. D., Sun, L., Naik, T. J., Prasad, S. V. N., & Ardehali, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804570200 · Cited by 185
Dodos, F., Halbsguth, T., Erdmann, E., & Hoppe, U. C. (2008) · Clinical Research in Cardiology · doi:10.1007/s00392-007-0633-6 · Cited by 174
Carvedilol Protects against Doxorubicin-Induced Mitochondrial Cardiomyopathy
Santos, D. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9532 · Cited by 174
Molecular and cellular mechanisms of anthracycline cardiotoxicity
Chen, B., Peng, X., Pentassuglia, L., Lim, C. C., & Sawyer, D. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0005-5 · Cited by 172
Role of Biomarkers in Chemotherapy-Induced Cardiotoxicity
Cardinale, D., & Sandri, M. T. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.04.002 · Cited by 168
cTnT can be a useful marker for early detection of anthracycline cardiotoxicity
Kilickap, S., Barista, I., Akgul, E., Aytemir, K., Aksoyek, S., Aksoy, S., Celik, I., Kes, S., & Tekuzman, G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi152 · Cited by 167
Neilan, T. G. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl013 · Cited by 164
The role of Neuregulin-1β/ErbB signaling in the heart
Pentassuglia, L., & Sawyer, D. B. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.08.015 · Cited by 162
Wassmuth, R., Lentzsch, S., Erdbruegger, U., Schulz-Menger, J., Doerken, B., Dietz, R., & Friedrich, M. G. (2001) · American Heart Journal · doi:10.1067/mhj.2001.115436 · Cited by 160
de Korte, M. A., de Vries, E. G. E., Lub-de Hooge, M. N., Jager, P. L., Gietema, J. A., van der Graaf, W. T. A., Sluiter, W. J., van Veldhuisen, D. J., Suter, T. M., Sleijfer, D. T., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.06.024 · Cited by 160
Tokarska-Schlattner, M., Zaugg, M., da Silva, R., Lucchinetti, E., SCHAUB, M. C., Wallimann, T., & Schlattner, U. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01057.2004 · Cited by 159
Cadeddu, C., Piras, A., Mantovani, G., Deidda, M., Dessì, M., Madeddu, C., Massa, E., & Mercuro, G. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.05.037 · Cited by 159
Aortic Stiffness Increases Upon Receipt of Anthracycline Chemotherapy
Chaosuwannakit, N., D'Agostino, R., Hamilton, C. A., Lane, K. S., Ntim, W. O., Lawrence, J. A., Melin, S. A., Ellis, L. R., Torti, F. M., Little, W. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8527 · Cited by 157
Mackey, J. R., Clemons, M. J., Côté, M. A., Delgado, D., Dent, S. F., Paterson, A., Provencher, L., Sawyer, M. B., & Verma, S. (2008) · Current Oncology · doi:10.3747/co.2008.199 · Cited by 154
Self-citationKuramochi, Y., Guo, X., & Sawyer, D. B. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.04.007 · Cited by 150
Mercuro, G., Dessalvi, C. C., Piras, A., Dessì, M., Madeddu, C., Deidda, M., Serpe, R., Massa, E., & Mantovani, G. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1124 · Cited by 147
Morris, P. G., Chen, C. C. L., Steingart, R. M., Fleisher, M., Lin, N., Moy, B., Come, S. E., Sugarman, S. M., Abbruzzi, A., Lehman, R. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1359 · Cited by 143
Daugaard, G., Lassen, U., Bie, P., et al. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2004.03.009 · Cited by 139
Mouridsen, H. T., Keshaviah, A. P., Coates, A. S., Rabaglio, M., Castiglione‐Gertsch, M., Sun, Z., Thurlimann, B. J. K., Mauriac, L., Forbes, J., Paridaens, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1665 · Cited by 137
Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review
Lal, S., Mahajan, A., Chen, W. N., & Chowbay, B. (2010) · Current Drug Metabolism · doi:10.2174/138920010791110890 · Cited by 135
Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training
Haykowsky, M. J., Mackey, J. R., Thompson, R. B., Jones, L. W., & Paterson, D. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0628 · Cited by 127
Self-citationSandri, M. T., Cardinale, D. M., Zorzino, L., Passerini, R., Lentati, P., Martinoni, A., Martinelli, G., & Cipolla, C. M. (2003) · Clinical Chemistry · doi:10.1373/49.2.248 · Cited by 123
Cuppone, F., Bria, E., Verma, S., Pritchard, K. I., Gandhi, S., Carlini, P., Milella, M., Nisticò, C., Terzoli, E., Cognetti, F., et al. (2007) · Cancer · doi:10.1002/cncr.23171 · Cited by 122
Spector, N. L., Yarden, Y., Smith, B. L., Lyass, L., Trusk, P. B., Pry, K. J., Hill, J. E., Xia, W., Seger, R., & Bacus, S. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701286104 · Cited by 122
Beauclair, S., Formento, P., Fischel, J., Lescaut, W., Largillier, R., Chamorey, E., Hofman, P. M., Ferrero, J.-M., Pagès, G., & Milano, G. A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm181 · Cited by 121
Agus, D. B., Sweeney, C. J., Morris, M. J., Mendelson, D. S., McNeel, D. G., Ahmann, F. R., Wang, J., Derynck, M. K., Ng, K., Lyons, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0649 · Cited by 116
Scintigraphic Techniques for Early Detection of Cancer Treatment–Induced Cardiotoxicity
de Geus‐Oei, L., Mavinkurve‐Groothuis, A. M. C., Bellersen, L., Gotthardt, M., Oyen, W. J. G., Kapusta, L., & van Laarhoven, H. W. M. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.082784 · Cited by 113
The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy
Bien, S., Riad, A., Ritter, C. A., Gratz, M., Olshausen, F., Westermann, D., Grube, M., Krieg, T., Ciecholewski, S., Felix, S. B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1344 · Cited by 111
Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity
Huelsenbeck, J., Henninger, C., Schad, A., Lackner, K. J., Kaina, B., & Fritz, G. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.65 · Cited by 98
Neuregulin-1β is Associated with Disease Severity and Adverse Outcomes in Chronic Heart Failure
Ky, B., Kimmel, S., Safa, R., Putt, M., Sweitzer, N., Fang, J. C., Sawyer, D., & Cappola, T. (2009) · Circulation · doi:10.1161/circulationaha.109.856310 · Cited by 98
Long term effects of tamoxifen on blood lipid values in breast cancer.
Dewar, J. A., Horobin, J. M., PREECE, P. E., Tavendale, R., Tunstall‐Pedoe, H., & Wood, R. A. (1992) · BMJ · doi:10.1136/bmj.305.6847.225 · Cited by 94
Ewer, M. S., & Glück, S. (2009) · Cancer · doi:10.1002/cncr.24219 · Cited by 91
Pituskin, E., Haykowsky, M. J., Mackey, J. R., Thompson, R. B., Ezekowitz, J. A., Koshman, S. L., Oudit, G. Y., Chow, K., Pagano, J. J., & Paterson, D. I. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-318 · Cited by 89
Self-citationKeung, E. C., Toll, L., Ellis, M., & Jensen, R. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115241 · Cited by 86
Cardiotoxicity of Trastuzumab in Clinical Practice
McArthur, H. L., & Chia, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070065 · Cited by 85
Assessment of Anthracycline Cardiomyopathy by Endomyocardial Biopsy
Mackay, B., Ewer, M. S., Carrasco, C. H., & Benjamin, R. S. (1994) · Ultrastructural Pathology · doi:10.3109/01913129409016291 · Cited by 84
Genotyping the risk of anthracycline-induced cardiotoxicity
Deng, S., & Wojnowski, L. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0024-2 · Cited by 79
Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes
Yamanaka, S., Tatsumi, T., Shiraishi, J., Mano, A., Keira, N., Matoba, S., Asayama, J., Fushiki, S., Fliss, H., & Nakagawa, M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02935-2 · Cited by 76
Trastuzumab containing regimens for early breast cancer
Moja, L., Brambilla, C., Compagnoni, A., & Pistotti, V. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006243 · Cited by 73
Pichon, M.-F., Cvitkovic, F., Hacène, K., Delaunay, J., Lokiec, F. M., Collignon, M. A., & Pecking, A. P. (2005) · PubMed · Cited by 71
Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice
Vedam, K., Nishijima, Y., Druhan, L. J., Khan, M., Moldovan, N. I., Zweier, J. L., & Ilangovan, G. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01047.2009 · Cited by 69
BRCA2 Protein Deficiency Exaggerates Doxorubicin-induced Cardiomyocyte Apoptosis and Cardiac Failure
Singh, K. K., Shukla, P. C., Quan, A., Desjardins, J., Lovren, F., Pan, Y., Garg, V., Gosal, S., Garg, A., Szmitko, P. E., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.292664 · Cited by 59
Neuregulin-1β1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes
Brero, A., Ramella, R., Fitou, A., Dati, C., Alloatti, G., Gallo, M. P., & Levi, R. C. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq238 · Cited by 56
Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Swain, S. M. (1998) · PubMed · Cited by 51
Dokainish, H., Sengupta, R., Pillai, M., Bobek, J., & Lakkis, N. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.070 · Cited by 50
Decreased Risk of Stroke Among 10-Year Survivors of Breast Cancer
Hooning, M. J., Dorresteijn, L. D. A., Aleman, B. M. P., Kappelle, A. C., Klijn, J. G. M., Boogerd, W. J., & van Leeuwen, F. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5516 · Cited by 47
Verma, S., & Ewer, M. S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq607 · Cited by 36
Watts, R. G., George, M., & Johnson, W. H. (2011) · Cancer · doi:10.1002/cncr.26481 · Cited by 30
Bosch, X., Esteve, J., Sitges, M., de Caralt, T. M., Domènech, A., Ortiz-Pérez, J. T., Monzó, M., Morales‐Ruiz, M., Perea, R. J., & Rovira, M. (2011) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.03.008 · Cited by 27
Jones, L. W., Dolinsky, V. W., Haykowsky, M. J., Patterson, I., Jones, L. W., Allen, J. D., Scott, J. M., Rogan, K. J., Khouri, M., Hornsby, W., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-5024 · Cited by 14
Self-citation
Cited by
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,795
Self-citationZamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Thavendiranathan, P., Poulin, F., Lim, K.-D., Plana, J. C., Woo, A., & Marwick, T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.073 · Cited by 1,079
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeu192 · Cited by 1,058
Self-citation
Metadata
- Authors
- Khouri, M. G., Douglas, P. S., Mackey, J. R., Martin, M., Scott, J. M., Scherrer-Crosbie, M., & Jones, L. W.
- Venue
- Circulation
- Published
- 2012-12-04
- Volume
- 126
- Issue
- 23
- Pages
- 2749-2763
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2126727347
- Cited by
- 255
- References
- 141
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.